Spanish version of the susceptibility to e-cigarettes scale among Latino adolescents

% of

The purpose of this article is to present the Spanish version of the susceptibility to e-cigarettes scale. Data are from a randomized controlled trial to assess the immediate impact of vaping prevention graphic messages among 362 Black and Latino adolescents (aged 12-17 years), with equal representation between the two groups [6][7] . The study design and results are described thoroughly in a previous publication 6 . A forward-backward methodology was used to translate the susceptibility to e-cigarettes scale into Spanish 8 . Moreover, a Community Advisory Board of Latino adolescents reviewed and approved the translation. Table 1 shows the translation of the scale. Cronbach's alpha was used to assess the internal consistency reliability of the questionnaire 9 .
Sixty-five Latino adolescents completed the susceptibility to e-cigarettes scale in Spanish, as part of the baseline survey. The Cronbach's alpha coefficient of the Spanish version of the susceptibility to e-cigarettes scale was 0.74. The introduced Spanish version of the susceptibility to e-cigarettes scale shows an acceptable internal consistency reliability, with potential applications in both research and clinical settings. The use of validated Spanish-language assessment tools -developed in collaboration with community members -is vital to advance vaping prevention research among Latinos. Future research should examine other aspects of instrument validity (e.g. predictive validity) and involve larger samples.

CONFLICTS OF INTEREST
The authors have each completed and submitted an ICMJE Form for Disclosure of Potential Conflicts of Interest. The authors declare that they have no competing interests, financial or otherwise, related to the current work. Since the initial planning of the work, all authors report funding from The National Cancer Institute of the National Institutes of Health and the Food and Drug Administration Center for Tobacco Products under Award Number U54CA228110. During the past 36 months, A.P. Cupertino, reports receiving grants from the National Institutes for Health (NIH/ NCI R01CA212189, NIH/NIMHD R42MD010318); F. Cartujano-Barrera reports receiving grants from Prevent Cancer Foundation, American Lung Association, and American Association for Cancer Research, and support to attend meetings from the Society for Research on Nicotine and Tobacco; M. P. Rivera reports receiving a grant from the National Institutes for Health (NIH/NCI R01CA212014), and royalties from the SU2Cancer: Southeastern Consortium for Lung Cancer Health Equity, support for attending Round Table meetings from American Cancer Society/National Lung Cancer, and other support from the American Thoracic Society.

FUNDING
Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) Center for Tobacco Products (Award Number U54CA228110). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the FDA.

ETHICAL APPROVAL AND INFORMED CONSENT
The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of the University of Rochester Medical Center (Approval number: STUDY00006267; Date: June 18, 2021). Parents'/guardians' permission and adolescents' assent was obtained from all subjects involved in the study.

DATA AVAILABILITY
The datasets generated for this study are available on request to the corresponding author.

PROVENANCE AND PEER REVIEW
Not commissioned; internally peer reviewed.

DISCLAIMER
The views and opinions expressed in this article are those of the authors.